{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=AdverseEvent&page=24",
    "query": {
      "condition": "AdverseEvent",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 927,
    "total_pages": 93,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=AdverseEvent&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=AdverseEvent&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T14:46:15.007Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01875861",
      "title": "Monitoring and Management for Metabolic Side Effects of Antipsychotics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mental Health",
        "Psychotic Disorders"
      ],
      "interventions": [
        {
          "name": "Evidence-Based Quality Improvement Plus Facilitation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-01",
      "completion_date": "2017-04",
      "has_results": true,
      "last_update_posted_date": "2019-02-12",
      "last_synced_at": "2026-10-23T14:46:15.007Z",
      "location_count": 1,
      "location_summary": "North Little Rock, Arkansas",
      "locations": [
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01875861"
    },
    {
      "nct_id": "NCT02115256",
      "title": "Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "External Cephalic Version"
      ],
      "interventions": [
        {
          "name": "Intravenous Terbutaline",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Nitroglycerine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yaakov Beilin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2014-07",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-10-23T14:46:15.007Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02115256"
    },
    {
      "nct_id": "NCT01613651",
      "title": "Robotic Assisted Laparoscopic Prostatectomy With or Without Pelvic Drain Placement in Reducing Adverse Events After Surgery in Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Perioperative/Postoperative Complications",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "robot-assisted laparoscopic surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "intraoperative complication management/prevention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 191,
      "start_date": "2012-08-24",
      "completion_date": "2017-09-11",
      "has_results": false,
      "last_update_posted_date": "2017-09-14",
      "last_synced_at": "2026-10-23T14:46:15.007Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01613651"
    },
    {
      "nct_id": "NCT05116813",
      "title": "Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Parkinson Disease",
        "Dyskinesia, Drug-Induced",
        "Dyskinesias"
      ],
      "interventions": [
        {
          "name": "Dipraglurant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Addex Pharma S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 17,
      "start_date": "2021-10-25",
      "completion_date": "2022-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-10-23T14:46:15.007Z",
      "location_count": 7,
      "location_summary": "Augusta, Georgia • Kansas City, Kansas • New Brunswick, New Jersey + 4 more",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05116813"
    },
    {
      "nct_id": "NCT01789047",
      "title": "Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Parkinson's Disease",
        "Drug Induced Dyskinesia"
      ],
      "interventions": [
        {
          "name": "Topiramate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Amantadine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "30 Years to 90 Years"
      },
      "enrollment_count": 42,
      "start_date": "2013-03",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-10-23T14:46:15.007Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01789047"
    },
    {
      "nct_id": "NCT02041858",
      "title": "Effect of Altered Alarm Settings on Patient Adverse Events and Alarm Signal Frequency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Physiologic Monitoring",
        "Alarms"
      ],
      "interventions": [
        {
          "name": "Altered Alarm Settings",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 22,
      "start_date": "2013-04",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2017-03-06",
      "last_synced_at": "2026-10-23T14:46:15.007Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02041858"
    },
    {
      "nct_id": "NCT05738850",
      "title": "Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Generalized Anxiety Disorder (GAD)",
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "ABBV-932",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 104,
      "start_date": "2023-02-15",
      "completion_date": "2024-05-31",
      "has_results": false,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-10-23T14:46:15.007Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Grayslake, Illinois",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05738850"
    },
    {
      "nct_id": "NCT05054218",
      "title": "COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Covid19",
        "SARS-CoV2 Infection"
      ],
      "interventions": [
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 336,
      "start_date": "2021-09-10",
      "completion_date": "2022-08-29",
      "has_results": false,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-10-23T14:46:15.007Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05054218"
    },
    {
      "nct_id": "NCT07204990",
      "title": "BELUGA: Better to Exchange ETT for LMA Before Extubation in Children Under General Anaesthesia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Endotracheal Extubation",
        "Airway Anesthesia",
        "Paediatric"
      ],
      "interventions": [
        {
          "name": "Direct removal of endotracheal tube",
          "type": "PROCEDURE"
        },
        {
          "name": "Laryngeal mask airway inserted following deep extubation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Telethon Kids Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "0 Years to 16 Years"
      },
      "enrollment_count": 1400,
      "start_date": "2026-02-06",
      "completion_date": "2029-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-23T14:46:15.007Z",
      "location_count": 2,
      "location_summary": "Winston-Salem, North Carolina • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07204990"
    },
    {
      "nct_id": "NCT02126020",
      "title": "Topical Infliximab in Autoimmune Eyes With Keratoprosthesis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stevens-Johnson Syndrome",
        "Toxic Epidermal Necrolysis (Lyell) Syndrome",
        "Mucous Membrane Pemphigoid"
      ],
      "interventions": [
        {
          "name": "topical infliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "James Chodosh, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-11",
      "completion_date": "2017-04-03",
      "has_results": false,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-10-23T14:46:15.007Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02126020"
    }
  ]
}